{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:11:31Z","timestamp":1789269091788,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approximately one\u2010third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high\u2010risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4\u20137, enrolled in the ECHELON\u20101 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A\u00a0+\u00a0AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first\u2010line therapy after a median follow\u2010up of 37.1 months. Among patients treated with A\u00a0+\u00a0AVD (\n                    <jats:italic>n\u00a0<\/jats:italic>\n                    =\u00a0664) or ABVD (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0670), 64% had Stage IV disease and 26% had an IPS of 4\u20137. Patients with Stage IV disease treated with A\u00a0+\u00a0AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537\u20130.973;\n                    <jats:italic>p\u00a0=<\/jats:italic>\n                    \u00a00.032). Similar improvements were seen in the subgroup of patients with IPS of 4\u20137 (HR, 0.588; 95% CI, 0.386\u20130.894;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.012). The most common adverse events (AEs) in A\u00a0+\u00a0AVD\u2010treated versus ABVD\u2010treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4\u20137, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high\u2010risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON\u20101 shows a favorable benefit\u2010risk balance in high\u2010risk patients.\n                  <\/jats:p>","DOI":"10.1002\/hon.2838","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T23:13:36Z","timestamp":1611011616000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced\u2010stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high\u2010risk patients from the ECHELON\u20101 study"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"first","affiliation":[{"name":"Department of Haematology and Phase 1 Unit Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-2926","authenticated-orcid":false,"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Hematology Faculty of Medicine, University of Debrecen  Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department Institut Catal\u00e0 d'Oncologia\u2010Hospitalet and Institut d'Investigacions Biom\u00e8diques de Bellvitge (IDIBELL) Universitat de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer BC Cancer  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-6250","authenticated-orcid":false,"given":"Alice","family":"S\u00fdkorov\u00e1","sequence":"additional","affiliation":[{"name":"University Hospital and Faculty of Medicine  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-2815","authenticated-orcid":false,"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Osaka University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-7480","authenticated-orcid":false,"given":"Neil S.","family":"Chua","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1420-5563","authenticated-orcid":false,"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ko\u0159en","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine General University Hospital  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann Steward","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Molina","sequence":"additional","affiliation":[{"name":"CHU de Grenoble  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Engley","sequence":"additional","affiliation":[{"name":"Seattle Genetics  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Fenton","sequence":"additional","affiliation":[{"name":"Seattle Genetics  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Jolin","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-4510","authenticated-orcid":false,"given":"Rachael","family":"Liu","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9319-7820","authenticated-orcid":false,"given":"Ashish","family":"Gautam","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2054-7412","authenticated-orcid":false,"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[{"name":"Research and Innovation Department Centre Antoine Lacassagne  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9774"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30140-6"},{"key":"e_1_2_9_8_1","volume-title":"Cancer Stat Facts: Hodgkin Lymphoma","year":"2020"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003127"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21349"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.655"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2543"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0910"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T18:48:58Z","timestamp":1693594138000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/hon.2838"],"URL":"https:\/\/doi.org\/10.1002\/hon.2838","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2838\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2838\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2838\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2838\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2838\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"2020-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}